Yellow Fever Treatment Market, By Transmission Type (Sylvatic Yellow Fever, Intermediate Yellow Fever, Urban Yellow Fever), By Treatment Type (Vaccines, Medications, Others), By Application (Hospitals, Clinics, Community Health Centers, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
Yellow Fever Treatment Market Size and Share Analysis – 2026 To 2033
The Global Yellow Fever Treatment Market size is anticipated to grow at a steady CAGR of 3.7%, with an estimated value of approximately USD 564.2 Mn in 2026 and is expected to reach nearly USD 728.5 Mn in 2033. The growth is mainly driven by the increasing burden of vector-borne infectious illnesses, growing worldwide focus on outbreak preparedness, increasing immunization programs and advances in supportive care and essential treatment facilities in endemic locations. The World Health Organization (WHO) estimates that a single dose of the yellow fever vaccine provides life-long immunity in 99% of those vaccinated. Therefore, vaccination for yellow fever is the best preventive measure and significantly reduces the need for preventive healthcare infrastructure compared to curative care alone.
Key Takeaways
Sylvatic Yellow Fever segment dominates with an estimated 65% share of total reported cases in 2026, driven by sustained zoonotic transmission cycles between non-human primates and forest-dwelling mosquitoes in endemic regions of Africa and South America. This makes sylvatic transmission the primary driver of disease incidence and the largest contributor in modeled “market burden” frameworks.
Vaccines segment is expected to dominate the market with 68% share in 2026. The segment’s dominance is driven by the fact that yellow fever is primarily managed through preventive immunization rather than curative drug-based treatment. WHO-recommended mass vaccination campaigns, international travel vaccination requirements, and high single-dose vaccine efficacy (providing long-term immunity in most cases) continue to make vaccines the central revenue and volume contributor in the market.
Hospitals segment to dominate with 55% share in 2026 This dominance is because hospitals are the main point of vaccination administration, outbreak diagnosis, severe case management and worldwide travel immunization certification. Clinical management in hospital settings is strictly supportive which increases reliance on inpatient care for managing complications such as organ failure, hemorrhage, and severe dehydration. This reinforces hospitals as the primary care delivery setting for advanced cases rather than outpatient clinics.
North America is expected to acquire the prominent share of 40% in the global Yellow Fever treatment market in 2026. The region’s dominance is primarily driven by high international travel vaccination demand, strong availability of licensed yellow fever vaccines, advanced public health surveillance systems, and strict vaccination requirements for travelers entering endemic regions. According to the Centers for Disease Control and Prevention highlights that yellow fever vaccination is a key preventive measure for travelers to endemic areas, and vaccination is recommended or required depending on destination risk assessment, which significantly supports vaccine demand in North America.
Market Drivers
Rising Outbreak Risk & Expanding Vector Distribution is Driving the Yellow Fever Treatment Market
The growing occurrence of yellow fever outbreaks, especially in the endemic regions of Africa and some areas of South America, is a major factor fueling the yellow fever treatment market. The risk of transmission on the other hand is dramatically growing due to climate variability, urbanization and expansion of Aedes and Haemagogus mosquitoes’ habitats, all of which are boosting demand for immunization, diagnostics and supportive care services.
According to the WHO estimates that yellow fever causes 200,000 illnesses and about 30,000 fatalities per year worldwide, with most cases in Africa. WHO also points out that nearly 47 nations are at danger, where epidemics can quickly spiral in sub-immunized populations.
Climate Change–Driven Expansion of Mosquito Habitats is Increasing Disease Transmission Risk
Rising temperatures, altered rainfall patterns and increasing humidity are expanding the geographic range of Aedes aegypti mosquitoes, increasing the possibility for yellow fever transmission in both endemic and previously low-risk areas. This is raising demand for preventative immunization and bolstering outbreak preparedness efforts around the world.
According to the World Health Organization (WHO) warns that mosquito-borne diseases like as yellow fever are creeping into new altitude and urban zones that were previously unfriendly to the vectors and that the risk of epidemics among unprotected populations is substantially greater.
Current Events and Their Impact on the Yellow Fever Treatment Market
Current Event
Description and its Impact
WHO Expansion of Emergency Yellow Fever Vaccination Campaigns in Africa (2024–2026)
Description: WHO, with Gavi and UNICEF, has increased preventive mass vaccination efforts in high-risk countries in Africa, including multi-country epidemic preparedness and rapid response immunization campaigns to under-immunized populations. There is a growing focus on urban outbreaks using combination immunization and surveillance strategies.
Impact: This is leading to a huge surge in demand for yellow fever vaccinations, cold chain logistics and emergency stockpile management. It also improves the public procurement cycles and speeds up the establishment of vaccine distribution infrastructure in endemic places, which directly contributes to the preventative component of the yellow fever treatment market.
WHO Declaration of Ongoing Risk of Urban Yellow Fever Resurgence (2024 Update)
Description: The WHO has reiterated that urban yellow fever is a global threat, driven by decreasing immunity in some populations and increasing urban mosquito density. The association cautions about the threat of catastrophic outbreaks in congested cities where immunization rates are low.
Impact: This has raised global awareness about routine immunization, needs for travel vaccinations and preparedness for urban outbreaks. It is driving continuous vaccine procurement and reinforcing government investments in preventative immunization systems, particularly in rapidly urbanizing parts of Africa and South America.
Why is Sylvatic Yellow Fever Acquiring the Largest Share?
By disease type, the Sylvatic Yellow Fever sector is predicted to account for 65% of all reported cases in 2026, due to spillover from non-human primates to humans continuing in woodland areas, mostly in sub-Saharan Africa and parts of South America. Sylvatic transmission through prolonged zoonotic reservoirs is the major cause of epidemics in endemic locations.
According to the WHO surveillance reports indicated that in early 2025 there were 212 confirmed cases and 85 deaths in the Americas, mainly from forest-exposed areas, confirming the sylvatic dominance of the outbreak pattern.
In March 2026, the Pan American Health Organization (PAHO) reported continuing yellow fever transmission in several countries in South America with a major change in epidemiology with the expansion from traditional Amazon endemic areas to new non-endemic and forest boundary areas.
Based on treatment type, the Vaccines segment is forecast to account for 68% market share by 2026 owing to its strong preventive capacity and incorporation into the vaccination program in endemic countries. One dose of the vaccine provides lifetime immunity against yellow fever infection.
According to WHO reports that following large-scale vaccination campaigns, many endemic areas in high-risk African countries now have more than 80 percent coverage of their populations with vaccines. This is the critical level to stop the disease spread and preserve herd immunity.
In October 2025, the Government of Bangladesh, in collaboration with Gavi, UNICEF and WHO, formally launched a nationwide Typhoid Conjugate Vaccine (TCV) program to vaccinate some 50 million children aged 9 months to under 15 years.
Hospitals Segment Leads the Market
Hospitals segment is projected to hold the largest market of 55% in 2026 end-user due to clinical management of severe yellow fever cases with hepatic failure, hemorrhagic sequelae, and multi-organ dysfunctions needing critical care support.
The World Health Organization (WHO) estimates that 15–30% of patients with severe yellow fever may die in the absence of appropriate supportive care in a hospital setting, further emphasizing hospitals as the principal treatment venue for advanced disease.
In November 2025, SMS Medical College and Hospital, Jaipur (India), launched a dedicated “Yellow Fever and Adult Vaccination Outpatient Department (OPD)” under its Department of Preventive and Social Medicine.
Yellow Fever Treatment Market Trends
The high disease burden continues to fuel global market dominance of vaccines, with the WHO estimating 67,000 to 173,000 severe yellow fever infections and 31,000 to 82,000 deaths each year, most of which are in Africa and caused by sylvatic transmission cycles.
Emergency vaccine stockpiles enhance epidemic response capacity and contribute to supply chain stability. For example, WHO-managed global stockpiles hold 6 million doses of yellow fever vaccine annually to facilitate quick response to outbreaks through the International Coordinating Group (ICG).
High transmission severity is a major market driver in urban outbreak risk. WHO reports that 50% of patients may die in severe phases of infection hence increasing demand for supportive treatment in hospitals.
North America Dominates the Yellow Fever Treatment Market
North America is expected to hold 40% share of the global Yellow Fever treatment market by 2026, owing to high demand for travel vaccinations, advanced healthcare infrastructure and high compliance of international immunization requirements among travelers to endemic regions.
Additionally, WHO also reported that approximately 105 million individuals were vaccinated under the Yellow Fever Initiative in West Africa, which resulted in significant reductions in epidemic activity.
In November 2025, Sanofi (Sanofi Pasteur) reiterated its position as the key supplier for the WHO/UNICEF global yellow fever vaccine emergency stockpile, allowing the quick mobilization of doses in case of outbreaks in Africa and South America. The company emphasized its capacity for supplying millions of vaccine doses within the required timeframe (up to 72 hours) via the WHO ICG system.
Asia Pacific is the Fastest-Growing Region in the Yellow Fever Treatment Market
The Asia Pacific is predicted to be the fastest growing region due to increasing outward travel to endemic countries, improved vaccination infrastructure, and increasing government focus on infectious disease preparation and vaccine accessibility.
Asia-Pacific remains a high-risk importation region given the massive travel exposure, as WHO notes that hundreds of millions of international travelers travel from Asia-Pacific to Africa and South America annually, creating an increased demand for pre-travel yellow fever vaccination services and travel certification systems.
United States Yellow Fever Treatment Market Trends
The United States represents a key non-endemic but high-value market for yellow fever vaccine services, supported mostly by travel medicine infrastructure, CDC certification requirements, and robust hospital-based immunization programs.
The U.S. has a national network of CDC-certified Yellow Fever Vaccination Centers, which are critical for administration of the vaccine and issuance of the International Certificate of Vaccination (ICVP), often required for travel to endemic areas of Africa and South America.
China Yellow Fever Treatment Market Trends
China is a non-endemic country for yellow fever but remains a high-risk importation and preparedness market, driven by outbound travel, surveillance systems, and strict infectious disease control policies.
In July 2025, reports based on China CDC surveillance data (published through China CDC Weekly and cited in China Daily coverage) confirmed a large outbreak of chikungunya fever in Foshan, Guangdong Province, China, which prompted enhanced national vector-control and emergency response efforts.
Who are the Major Companies in Yellow Fever Treatment Industry
Some of the major key players in Yellow Fever TreatmentMarket are Sanofi Pasteur SA, Janssen, Pfizer Inc., BIOCRYST PHARMACEUTICALS, INC., Tychan Pte. Ltd., Johnson & Johnson Services, Inc., Takeda Pharmaceutical Company Limited, Bayer AG, GlaxoSmithKline plc, Bio-Manguinhos, Institut Pasteur de Dakar, and FSUE Chumakov.
Key News
In April 2026, the Coalition for Epidemic Preparedness Innovations (CEPI) and the Pasteur Network announced a new Memorandum of Understanding (MoU) to enhance global and regional collaboration in vaccine research and development, clinical trials, biosafety, and outbreak preparedness systems.
In March 2024, Bio-Manguinhos/Fiocruz (Brazil) announced a major optimization and expansion of its yellow fever vaccine production capacity, increasing output from approximately 60 million doses per year to about 107–120 million doses annually.
Market Report Scope
Yellow Fever Treatment Market Report Coverage
Report Coverage
Details
Base Year:
2025
Market Size in 2026:
USD 564.2 Mn
Historical Data for:
2020 To 2024
Forecast Period:
2026 To 2033
Forecast Period 2026 to 2033 CAGR:
3.7%
2033 Value Projection:
USD 728.5 Mn
Geographies covered:
North America: U.S., Canada
Latin America: Brazil, Argentina, Mexico, Rest of Latin America
Europe: Germany, U.K., France, Spain, Italy, Russia, Rest of Europe
Asia Pacific: China, Japan, India, Australia, South Korea, ASEAN, Rest of Asia Pacific
Middle East: GCC Countries, Israel, Rest of Middle East
Africa: North Africa, Central Africa, South Africa
Analysts note that the market is fundamentally constrained by high manufacturing concentration, with only a few of WHO prequalified producers (Sanofi, Bio-Manguinhos, Institut Pasteur Dakar, FSUE Chumakov) serving global demand, thus rendering supply vulnerable at the height of outbreaks.
WHO-managed emergency response systems are dependent on the International Coordinating Group (ICG) yellow fever vaccine stockpile that has been used in the past in multi-million dose emergency campaigns during African outbreaks, highlighting the need for quick manufacturing scalability.
The disease is geographically confined, with WHO confirming 47 countries at risk spanning Africa and South America, meaning that regional preparedness and immunization infrastructure is a primary market driver rather than therapeutic innovation.
Analysts highlight that urbanization, climate change and vector expansion (Aedes aegypti presence across tropical regions) are ever-increasing the unpredictability of outbreaks, emphasizing the relevance of surveillance-driven vaccination demand over treatment-based demand.
Cold Chain Logistics & Vaccine Distribution Providers
Others
Databases
World Health Organization (WHO) Global Health Observatory
UNICEF Supply Division Vaccine Data
Pan American Health Organization (PAHO) Immunization Data
Gavi Vaccine Alliance Dashboard
Our World in Data – Vaccination & Infectious Disease Dataset
World Bank Health, Nutrition & Population Data
CDC WONDER & Travelers’ Health Data
IHME Global Burden of Disease Study
Others
Magazines
The Lancet Infectious Diseases
BMJ Global Health
Vaccine Journal (Elsevier)
Nature Medicine
Clinical Infectious Diseases Journal Insights
Health Policy Watch
STAT News (Global Health Section)
Others
Journals
World Health Organization Weekly Epidemiological Record (WER)
Emerging Infectious Diseases (CDC Journal)
Bulletin of the World Health Organization
PLOS Neglected Tropical Diseases
Vaccine Journal
International Journal of Infectious Diseases
Journal of Travel Medicine
Others
Newspapers
Reuters Health
BBC Health
The Guardian (Global Health)
Financial Times (Healthcare Section)
Bloomberg Health
The New York Times (Global Health Coverage)
The Economic Times (India Health Reports)
Business Standard Health Coverage
Others
Associations
World Health Organization (WHO)
Gavi, the Vaccine Alliance
Pan American Health Organization (PAHO)
Africa CDC (African Centres for Disease Control and Prevention)
CEPI (Coalition for Epidemic Preparedness Innovations)
UNICEF Immunization Programs
Red Cross / Red Crescent Health Programs
Others
Public Domain Sources
WHO Yellow Fever Fact Sheet & Surveillance Reports
WHO International Coordinating Group (ICG) Vaccine Stockpile Data
PAHO Yellow Fever Epidemiological Updates
CDC Yellow Fever Travel Health Notices
Gavi Vaccine Investment Strategy Reports
World Bank Infectious Disease & Health Security Reports
CEPI Pandemic Preparedness Publications
GitHub / Open Data for Disease Surveillance Tools (supporting analytics systems)
Others
Proprietary Elements
CMI Data Analytics Tool
Proprietary CMI Existing Repository of information for last 10 years.
Share
Share
About Author
Vipul Patil is a dynamic management consultant with 6 years of dedicated experience in the pharmaceutical industry. Known for his analytical acumen and strategic insight, Vipul has successfully partnered with pharmaceutical companies to enhance operational efficiency, cross broader expansion, and navigate the complexities of distribution in markets with high revenue potential.
Missing comfort of reading report in your local language? Find your preferred language :
The Global Yellow Fever Treatment Market is expected to reach approximately USD 728.5 Mn in 2033, growing from USD 564.2 Mn in 2026 at a CAGR of 3.7% during the forecast period.
Major players include Sanofi Pasteur SA, Janssen, Pfizer Inc., BIOCRYST Pharmaceuticals, Tychan Pte. Ltd., Johnson & Johnson Services, Takeda Pharmaceutical Company Limited, Bayer AG, GlaxoSmithKline plc, Bio-Manguinhos, Institut Pasteur de Dakar, and FSUE Chumakov.
The key challenges include limited vaccine manufacturing capacity during outbreak surges, high dependency on a small number of WHO-prequalified producers, cold-chain logistics limitations, and uneven vaccination coverage in endemic regions.
Market growth is driven by rising global vaccination programs under WHO EYE strategy, increasing international travel to endemic regions, expansion of immunization campaigns, climate-driven vector spread, and strengthening outbreak preparedness systems.
The Yellow Fever Treatment Market is anticipated to grow at a CAGR of 3.7% between 2026 and 2033.
North America is expected to account for the largest market share of around 40% in 2026, driven by strong travel vaccination demand, advanced healthcare infrastructure, and strict immunization requirements.
Governments prioritize vaccination because yellow fever has a high fatality rate in severe cases (up to 50%), and vaccination provides lifelong immunity in 99% of vaccinated individuals, making prevention the most effective control strategy.
